You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The researchers are developing a clinical assay that would use multiple biomarkers to analyze low-abundance peptides indicative of preterm risk.
The test measures quantities of white blood cells and CD64 on the surface of neutrophils, enabling the immune system's response to sepsis to be monitored.
Researchers are working with the Australian Ministry of Health to commercialize a diagnostic test that employs the biomarker and could be available within two to five years.
An Alberta-based research group plans to launch a blood test that could improve the specificity of prostate cancer diagnosis and reduce the number of biopsies.
Market growth is providing opportunities for emerging diagnostic companies and a range of options for clinicians, included PCR and protein tests.
The company expects to use its centrifugal microfluidic platform to launch a dengue assay early in 2018 and a Zika-dengue assay later in 2018.
Biocartis and MRCT are planning to develop a range of molecular diagnostic assays for Biocartis' fully automated Idylla platform.
The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.
The researchers said that they are developing a fiber probe that could generate a Bessel beam that could be inserted into arteries to obtain internal images.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.